Klin Farmakol Farm. 2025;39(2):117-121 | DOI: 10.36290/far.2025.040

Conservative treatment od endometriosis

Martin Trhlík
Gynekologicko-porodnické oddělení Nemocnice AGEL Nový Jičín, a. s.
EuroEndoCert akreditované centrum pro léčbu endometriózy

Endometriosis is a chronic gynaecological condition affecting up to 10 % of women of reproductive age. Fertility disorders, pain, and organ involvement significantly impact the quality of life and health of those affected. The socioeconomic burden is considerable, with substantial resources allocated to treatment. Management includes both radical surgical approaches and conservative methods, namely the administration of various groups of medicinal products. Analgesics are used to alleviate painful symptoms. Hormonal therapies include progestins alone or in combination with oestrogens, which influence the activity of endometriotic lesions. Another group of modern drugs employed in the conservative treatment of endometriosis are GnRH agonists and GnRH antagonists. In particular, GnRH antagonists combined with oestrogen-progestin therapy rank among the most effective treatment options. The article also discusses further possibilities for alternative therapies and outlines the future development of conservative treatment options and diagnostic approaches for endometriosis.

Keywords: endometriosis, estagens, antiflogistic drugs analgesics, GnRH agonist, GnRH antagonist.

Accepted: July 3, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trhlík M. Conservative treatment od endometriosis. Klin Farmakol Farm. 2025;39(2):117-121. doi: 10.36290/far.2025.040.
Download citation

References

  1. . World Health Organization. Endometriosis - Key Facts. [Internet]. World Health Organization; 2023 [cit. 2025-04-024]. Available from: https://www.who.int/news-room/fact-sheets/detail/endometriosis.
  2. . Becker CM, et al. ESHRE Guideline: Endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. Go to original source... Go to PubMed...
  3. . Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Eng J Med. 2020;382(13):1244-1256. Go to original source... Go to PubMed...
  4. . Ellis K, et al. Endometriosis Is Undervalued: A Call to Action. Frontiers in Global Women's Health. 2022;3:902371. 2673-5059. Go to original source... Go to PubMed...
  5. . García-Izquierdo L, et al. New Potential Pharmacological Options for Endometriosis Associated Pain. Int J Mol Sci. 2024;25(13):7068. Go to original source... Go to PubMed...
  6. . Wellbery C. Diagnosis and Treatment of Endometriosis. American Family Physician [Internet]. 1999;60(6): pp. 1753-1762 [cit. 2025-04-25]. Available from: https://www.aafp.org/pubs/afp/issues/1999/1015/p1753.html.
  7. . Pino MA. The pharmacologic management of endometriosis. US Pharmacist [Internet]. 2017;42(9):12-16 [cit. 2025-04-24]. Dostupné z: https://www.uspharmacist.com.
  8. . LI L, et al. Complementary therapy for endometriosis-related pelvic pain - Review. Journal of Endometriosis and Pelvic Pain Disorders. 2023;15(1):34-43. Doi: 10.1177/22840265231157362. Go to original source...
  9. . Cronkleton E. Yoga for Endometriosis: 8 Poses to Relieve Pelvic Pain. Healthline [Internet]. 2022 [cit. 2025-04-25]. Available from: https://www.healthline.com/health/fitness/yoga-for-endometriosis.
  10. . Mamillapalli HZ, Ramanaiah and Taylor, Hugh S. Predictive biomarkers may allow precision therapy of endometriosis. Journal of Endometriosis and Pelvic Pain Disorders. 2017;9(4):279-285. Go to original source... Go to PubMed...
  11. . Griffiths MJ, Horne AW, Gibson DA, et al. Endometriosis: recent advances that could accelerate diagnosis and improve care. Trends in Molecular Medicine. 2024;30(9):875-889. [cit. 2025-04-25]. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.